Robert Fabregat – CEO, Biocat
Robert Fabregat, CEO of Biocat, explains how health start-ups in the BioRegion of Catalonia managed to raise a record EUR 238 million in 2021 and why the Spanish region is…
The Cajal Institute in Madrid
Research in neuroscience has a longstanding tradition in Spain mostly inspired by Nobel Prize winner Santiago Ramón y Cajal and his disciples, for whom the “Instituto Cajal” (IC) was initially conceived in 1934. Five years later the Spanish Government created the National Research Council under the name of Consejo Superior de Investigaciones Cientificas (CSIC) and the IC became one of the first centers of this new Institution. The IC is one of the two CSIC centers fully devoted to research in Neuroscience. The Institute moved to its present location in downtown Madrid in a building of 4,500 m2 in 1989. Currently the IC houses 25 independent research teams and around 200 staff, with operating costs close to 9 K€/year.
From its inception the Cajal Institute has contributed to the advance in Neuroscience and has hosted and formed many of the neuroscientists working now in the different Spanish research and academic centers. Along almost one century of life, the Institute has become a center of worldwide reputation, building on the important contributions of its founder to the present day. Current staff of the Institute has been selected under a tight competitive system according to the high standards of the CSIC. Presently, the institute is organized in two departments: Functional and Systems Neurobiology, and Cellular, Molecular and Developmental Neurobiology, which intend to agglutinate research in all major areas of neuroscience. The focus of the IC research can be comprised in five major lines:
– Mechanisms of neural specification
– The neuro-vascular unit
– Processing of neural signals (a new line of work in neuro-prosthetics and bioengineering is being planned to be incorporated in the near future to reinforce this section)
– Neuroprotection and regeneration
– Systemic modulators of brain function
Contact information:
Cajal Institute (CSIC)
Avenida Doctor Arce 37
28002 Madrid.
Robert Fabregat, CEO of Biocat, explains how health start-ups in the BioRegion of Catalonia managed to raise a record EUR 238 million in 2021 and why the Spanish region is…
Alta Life Sciences is one of Catalonia’s top venture capital investor groups in the biotech sector. Montserrat Vendrell, partner and a pivotal figure in the development of the region’s life…
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
The Pasqual Maragall Foundation is a Spanish non-profit research organization dedicated to the research of Alzheimer’s disease. Its director, Arcadi Navarro, takes from his decades-long scientific career in genomics to…
VIVEbiotech is a Spanish CDMO specialised in the production of lentiviral vectors used in gene therapy. Its CEO, Dr Gurutz Linazasoro, tells the story of the company’s creation, comments on…
EATRIS, the European Infrastructure for Translational Medicine, is an EU-funded program that facilitates scientific collaboration amongst public institutions from 14 member states. Its scientific director, Dr Toni Andreu, explains how…
Javier Urzay, deputy director of Farmaindustria, the leading pharma industry association in Spain, discusses the main dynamics shaping the sector, including record levels of R&D investment and clinical trials, their…
Biogen’s managing director for Spain, Sergio Teixeira, reflects on the company’s key role in transforming multiple sclerosis and spinal muscular atrophy as examples of the American biotech giant commitment to…
Bial’s general manager for Spain and global director of its epilepsy franchise, Ana Álvarez, highlights the importance of the country for the organization – representing 25 percent of overall sales…
Soon after reaching its 60th anniversary, in 2015, the largest hospital in Catalonia and a group of sister institutions began working on the creation of a new type of campus.…
Dr Manel Juan is part of the team behind the development of the first European CAR-T-cell therapy to treat multiple myeloma, the second most common type of blood cancer. As…
Ángel Luis Rodríguez de la Cuerda, longtime secretary general of AESEG, the trade association of generic producers in Spain, comments on the key role played by generic medicines during the…
See our Cookie Privacy Policy Here
